P E Morris

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. pmc A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome
    Peter E Morris
    Altor BioScience Corp, Miramar, FL, USA
    BMC Pulm Med 12:5. 2012
  2. pmc A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock
    Peter E Morris
    Wake Forest University School of Medicine, Winston Salem, NC, USA
    Crit Care 16:R31. 2012
  3. pmc Receiving early mobility during an intensive care unit admission is a predictor of improved outcomes in acute respiratory failure
    Peter E Morris
    Pulmonary, Critical Care, Allergy and Immunologic Disease, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Am J Med Sci 341:373-7. 2011
  4. pmc A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults
    Peter E Morris
    Pulmonary Critical Care, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Crit Care 14:R125. 2010
  5. doi request reprint Early intensive care unit mobility therapy in the treatment of acute respiratory failure
    Peter E Morris
    Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Crit Care Med 36:2238-43. 2008
  6. ncbi request reprint Acute respiratory distress syndrome: pharmacological treatment options in development
    R D Hite
    Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Drugs 61:897-907. 2001
  7. ncbi request reprint Early intensive care unit mobility: future directions
    Peter E Morris
    Section on Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest University School of Medicine, Gray Building, Room 3141, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Crit Care Clin 23:97-110. 2007
  8. ncbi request reprint Moving our critically ill patients: mobility barriers and benefits
    Peter E Morris
    Pulmonary Medical, Room 3141 Gray Building, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Crit Care Clin 23:1-20. 2007
  9. ncbi request reprint Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated)
    Peter E Morris
    Pulmonary Medicine, Wake Forest University School of Medicine, 3rd Floor, Gray Building, 3325 Silas Creek Parkway, Winston Salem, NC 27103, USA
    Am J Surg 184:S19-24. 2002
  10. ncbi request reprint Drotrecogin alfa
    Michael J Raggio
    Pulmonary and Critical Care Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Drugs Today (Barc) 40:517-38. 2004

Detail Information

Publications21

  1. pmc A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome
    Peter E Morris
    Altor BioScience Corp, Miramar, FL, USA
    BMC Pulm Med 12:5. 2012
    ..This study was designed to determine the pharmacokinetic and safety profiles of ALT-836, an anti-TF antibody, in patients with ALI/ARDS...
  2. pmc A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock
    Peter E Morris
    Wake Forest University School of Medicine, Winston Salem, NC, USA
    Crit Care 16:R31. 2012
    ..Secondary outcomes related to pharmacokinetic (PK) and pharmacodynamic (PD) parameters...
  3. pmc Receiving early mobility during an intensive care unit admission is a predictor of improved outcomes in acute respiratory failure
    Peter E Morris
    Pulmonary, Critical Care, Allergy and Immunologic Disease, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Am J Med Sci 341:373-7. 2011
    ....
  4. pmc A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults
    Peter E Morris
    Pulmonary Critical Care, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Crit Care 14:R125. 2010
    ..Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults...
  5. doi request reprint Early intensive care unit mobility therapy in the treatment of acute respiratory failure
    Peter E Morris
    Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Crit Care Med 36:2238-43. 2008
    ..Despite the theoretical advantages of physical therapy to address this problem, it has not been shown that physical therapy initiated in the intensive care unit offers benefit...
  6. ncbi request reprint Acute respiratory distress syndrome: pharmacological treatment options in development
    R D Hite
    Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Drugs 61:897-907. 2001
    ....
  7. ncbi request reprint Early intensive care unit mobility: future directions
    Peter E Morris
    Section on Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest University School of Medicine, Gray Building, Room 3141, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Crit Care Clin 23:97-110. 2007
    ..Finally, we present a "roadmap" outlining future directions moving toward the development and testing of early ICU mobility therapies...
  8. ncbi request reprint Moving our critically ill patients: mobility barriers and benefits
    Peter E Morris
    Pulmonary Medical, Room 3141 Gray Building, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Crit Care Clin 23:1-20. 2007
    ..This article focuses particularly on how mobilization may improve quality of life for patients...
  9. ncbi request reprint Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated)
    Peter E Morris
    Pulmonary Medicine, Wake Forest University School of Medicine, 3rd Floor, Gray Building, 3325 Silas Creek Parkway, Winston Salem, NC 27103, USA
    Am J Surg 184:S19-24. 2002
    ....
  10. ncbi request reprint Drotrecogin alfa
    Michael J Raggio
    Pulmonary and Critical Care Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Drugs Today (Barc) 40:517-38. 2004
    ..A phase III clinical trial has demonstrated reduced mortality in severe sepsis patients receiving activated protein C...
  11. ncbi request reprint Comparison of 3 methods of detecting acute respiratory distress syndrome: clinical screening, chart review, and diagnostic coding
    April E Howard
    Wake Forest University School of Medicine, Winston Salem, NC, USA
    Am J Crit Care 13:59-64. 2004
    ..Although the incidence of acute respiratory distress syndrome has been studied, few researchers have prospectively assessed the search tool used to identify cases...
  12. pmc Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury
    Todd W Rice
    Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    JAMA 306:1574-81. 2011
    ....
  13. ncbi request reprint Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C
    Peter E Morris
    Division of Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27104, USA
    BioDrugs 16:403-17. 2002
    ..A phase III clinical trial has now demonstrated reduced mortality in patients with severe sepsis receiving activated protein C...
  14. doi request reprint A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome
    Peter E Morris
    Department of Pulmonary Critical Care, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Crit Care Med 36:782-8. 2008
    ..We examined the efficacy and safety of oxothiazolidine-4-carboxylic acid (OTZ), a free radical scavenger, in treating acute respiratory distress syndrome...
  15. ncbi request reprint Could multicenter trials optimize the cost of prolonged mechanical ventilation?
    Peter E Morris
    Am J Crit Care 17:8-10. 2008
  16. ncbi request reprint Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated)
    Peter E Morris
    Am J Crit Care 12:94-7. 2003
  17. ncbi request reprint Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis
    Todd W Rice
    Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Crit Care Med 34:2271-81. 2006
    ....
  18. ncbi request reprint Foundations of evidence-based practice: critical care trial networks
    Peter E Morris
    Am J Crit Care 17:190-3. 2008
  19. ncbi request reprint Passing the torch: the challenge of handoffs
    Kathleen Dracup
    Am J Crit Care 17:95-7. 2008
  20. ncbi request reprint Critical care professionalism in the age of pay-for-performance: from ICUs to outpatient critical care clinics
    Peter E Morris
    Am J Crit Care 16:200-3. 2007
  21. ncbi request reprint Nurse residency programs: preparing for the next shift
    Kathleen Dracup
    Am J Crit Care 16:328-30. 2007